

Financial Supervision Authority

Current report No. 58/2018

Date prepared: 2018-08-27

Abbreviated name of the issuer:

Mabion S.A.

Subject:

Receipt of payments for the implementation of the key stage of the cooperation agreement with Mylan Ireland.

Legal basis

Art.17 item 1 of MAR –confidential information

Content of the report:

With reference to Current Report No. 31/2016 of 8th of November 2016, concerning the conclusion of cooperation agreement with Mylan Ireland and Current Reports No. 36/2018 of 1st of June 2018 and 46/2018 of 21st of June 2018, concerning the acceptance for evaluation of marketing authorization application for MabionCD20 drug by the European Medicines Agency 'EMA', the Management Board of Mabion S.A. "the Company" hereby informs that on 27 August 2018 the Company obtained information on payment of USD 5 mln made by Mylan Ireland due to reaching the milestone of this agreement in the form of acceptance by EMA the registration documents for MabionCD20. The Company reminds that in accordance with concluded cooperation agreement, except for this payment, the Company after realising subsequent milestones will receive further payments in the total amount of up to USD 30 mln. The milestones currently still to be realised, on which depend future payments, are the approval for marketing authorisation of MabionCD20 and the progress in its commercialisation.